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ㅋ
Functional dyspepsia (FD) is a heterogeneous disorder associated with diverse pathophysiologic mechanisms. Studies have 
shown duodenal implications in the pathophysiology of FD. Duodenal hypersensitivity to acid, increased duodenal acid ex-
posure, and abnormal responses to duodenal lipids or released cholecystokinin have been observed in patients with FD. 
Moreover, there is evidence indicating duodenal immune activation in FD. Alterations in the number of duodenal eosinophils 
or intraepithelial lymphocytes have been reported in a subset of FD patients, particularly in patients with post-infectious FD. 
Whether these abnormalities in the duodenum play a crucial role in the generation of dyspeptic symptoms needs to be 
elucidated. Further investigations on the relationship between duodenal abnormalities and well-known pathophysiologic mech-
anisms of FD are required. Furthermore, the causative factors related to the development of duodenal abnormalities in FD war-
rant further study.
(J Neurogastroenterol Motil 2010;16:251-257)
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Introduction
Functional dyspepsia (FD) is a heterogeneous disorder char-
acterized by the presence of recurrent or persistent symptoms 
thought to originate in the gastroduodenal region without any or-
ganic, systemic or metabolic disease that is likely to explain the 
symptoms.
1 The pathophysiology of FD is considered to be mul-
tifactorial and not completely understood. Diverse pathophysio-
logic mechanisms have been suggested to be involved in FD. 
Several mechanisms have been proposed to be of importance, 
such as delayed gastric emptying, impaired proximal gastric ac-
commodation to a meal, gastric hypersensitivity to distension, ab-
normal duodenojejunal motility, and psychological disturbance.
2-6 
The stomach is traditionally believed to be mainly responsible 
for the genesis of dyspeptic symptoms. More recent studies have 
shown a number of sensorimotor and structural duodenal abnor-
malities in FD. Abnormal motor and sensory responses to duode-
nal acid or lipids have been demonstrated in patients with FD.
7-11 
Duodenal eosinophilia has been reported in FD patients.
12 Focal 
T-cell aggregates, decreased CD4+ cells and increased macro-
phage counts have been observed in the duodenum of patients 
with presumed post-infectious FD (PI-FD), which indicates im-
paired ability of the immune system to terminate the in-Kwang Jae Lee and Jan Tack
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flammatory response after acute insult.
13 These studies suggest 
the possibility that the duodenum is involved in the pathophysiol-
ogy of FD. Thus, in the present review, we aimed to address duo-
denal implications in the pathophysiology of FD. 
Abnormal Responses to
 Duodenal Acid in FD
The majority of FD patients have normal acid secretion,
14 
and gastric sensitivity to acid does not seem to be abnormal in 
those patients.
15 However, acid suppressive therapy provides 
symptomatic relief in a subset of FD patients.
16 Generally, acid 
suppressive therapy using proton-pump inhibitors seems benefi-
cial to the patients whose predominant symptoms are epigastric 
pain, burning sensation or gastroesophageal reflux symptoms. 
Samsom et al.
7 reported that duodenal acid infusion induced nau-
sea in a subset of FD patients, but not in healthy controls, sug-
gesting the presence of duodenal hypersensitivity to acid in FD 
patients. However, other studies found that dyspeptic symptoms 
such as nausea could be induced by duodenal acidification in 
healthy volunteers. Duodenal acid perfusion (0.2 N, 5 mL/min) 
for 15 minutes significantly increases symptom scores of dis-
comfort, bloating, nausea, and epigastric burning in healthy sub-
jects, compared with saline infusion.
17 Similarly, it has been dem-
onstrated that dyspeptic symptoms including fullness, bloating, 
nausea, satiety, epigastric burning and epigastric pain are induced 
by duodenal acid infusion in healthy volunteers.
18 In FD patients 
with prominent nausea, no significant differences in dyspeptic 
symptom scores were observed before and after duodenal acid in-
fusion, and between duodenal saline and acid infusion.
8 
Therefore, studies on the presence of duodenal hypersensitivity to 
acid in FD patients and its role in the pathophysiology of FD re-
main controversial. Since the number of study subjects in pre-
vious studies is small, larger studies are required. 
A 24-hour ambulatory duodenal pH monitoring has shown 
increased spontaneous duodenal acid exposure in FD patients.
8,19 
Duodenal acid exposure is reported to be significantly increased 
in FD patients during the daytime and after a meal. FD patients 
with increased spontaneous duodenal acid exposure have more 
severe dyspeptic symptoms than FD patients with normal duode-
nal acid exposure.
8 The possible mechanisms underlying in-
creased duodenal acid exposure present in a subset of FD pa-
tients include impaired duodenal acid neutralization and reduced 
duodenal acid clearance. Information on duodenal acid neutrali-
zation in FD patients is lacking. Whereas, reduced duodenal acid 
clearance due to a decreased duodenal motor response to acid has 
been demonstrated in FD patients.
7,8 Thus, reduced duodenal 
acid clearance seems to play a role in increasing duodenal acid ex-
posure in FD patients. 
The mechanism through which increased duodenal acid ex-
posure contributes to the generation of dyspeptic symptoms re-
mains to be elucidated. H
+ stimulates acid sensors such as tran-
sient receptor potential vanilloid 1 on the afferent nerves in the 
duodenum, followed by the release of calcitonin gene-related 
peptide and nitric oxide.
20 Therefore, acid can directly stimulate 
chemosensitive afferent pathways from the duodenum. Given 
that chemical stimulation is able to induce sensitization at the pe-
ripheral or the spinal level,
21 stimulation of duodenal afferents by 
acid may enhance gastric mechanosensitivity through the in-
duction of spinal sensitization. Indeed, a barostat study during 
duodenal infusion of saline or acid in healthy subjects revealed 
that duodenal acid infusion increased gastric mechanosen-
sitivity.
22
Intraduodenal acid infusion induces an enterogastric feed-
back, which suppresses propagated antral waves, stimulates iso-
lated pyloric pressure waves and delays gastric emptying.
23-25 The 
greater the concentration of acid in the duodenum, the greater is 
the inhibition of gastric emptying.
26 Accordingly, it is conceivable 
that increased duodenal acid exposure results in excessive enter-
ogastric feedback and delays gastric emptying. On the other 
hand, duodenal pH influences the regularity of the migrating 
motor complex and alkaline pH is needed for the initiation of a 
phase III.
27 Thus, prolonged duodenal acidification might inhibit 
the occurrence of a phase III. A recent study in healthy volun-
teers showed that duodenal acid perfusion did not affect the oc-
currence and duration of a phase III but induced antral 
hypomotility.
17 These findings suggest that duodenal acid-
ification induces or aggravates dyspeptic symptoms through its 
effects on gastric motor function. 
Therefore, the prolonged duodenal exposure to acid seems to 
be responsible for the generation of dyspeptic symptoms through 
the induction of gastric motor and sensory dysfunction.
Abnormal Responses to
 Du o d e n a l  L i p i d s  i n  F D
FD patients commonly report exacerbation of dyspeptic 
symptoms by fatty meals. Postprandial gastric hypersensitivity to 
distension plays a crucial role in the generation of dyspeptic 
symptoms in FD.
28 In contrast to healthy controls, dyspeptic pa-Duodenum in FD
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Table 1. Studies on Abnormal Responses to Duodenal Acid or Lipids in Functional Dyspepsia
Study Subjects Methods Results
Barbera et al,
29  10 FD patients Intraduodenal infusion of lipid or saline In contrast controls, dyspeptic patients 
  1995   10 controls Evaluation of gastric mechanosensitivity  have increased sensitivity to intraduodenal lipid 
Barbera et al,
31 18 FD patients Intraduodenal infusion of lipid or glucose Intraduodenal lipid but not glucose sensitizes 
  1995   9 controls Evaluation of gastric mechanosensitivity  the stomach to distension in FD patients but
 not in controls
Samsom et al,
7 12 FD patients Intraduodenal infusion of acid or saline Reduced duodenal acid clearance and duodenal 
  1999   10 controls Recording of duodenal pressures and pH  motor activity in FD patients
Feinle et al,
33 6 FD patients Intraduodenal infusion of lipid or saline Dexloxiglumide diminishes the effect of duodenal 
  2001    6 controls Administration of the CCK-A antagonist   lipids on gastric compliance and symptoms
 in FD patients
Björnsson et al,
11 20 FD patients Intraduodenal infusion of lipid Duodenal lipid infusion more enhances gastric 
  2003   13 controls Evaluation of gastric mechanosensitivity  mechanosensitivity in FD patients than in controls
Lee et al,
8 11 FD patients 24-hour ambulatory duodenal pH monitoring Increased spontaneous duodenal acid exposure
  2004   11 controls  in FD patients with prominent nausea
Bratten et al,
9 34 FD patients 48-hour ambulatory duodenal pH monitoring Greater duodenal acid exposure in FD patients,
  2009   25 controls  compared with controls
FD, functional dyspepsia; CCK, cholecystokinin.
tients have increased sensitivity to both gastric distension and in-
traduodenal lipid.
29 Most FD patients experienced nausea and 
bloating during lipid infusion, but remained asymptomatic dur-
ing saline infusion. Controls reported no symptoms during lipid 
infusion.
29 Duodenal lipid infusion can differentiate FD from 
healthy controls. After lipid infusion, 95% of FD patients are 
outside the normal range of controls for first sensation, bloating 
and/or discomfort thresholds to gastric distension, compared 
with 65% in the fasting state.
11 Different chemical composition of 
nutrients in the duodenum results in different sensory responses 
to gastric distension, which cannot be explained by changes in 
gastric tone.
30 Intraduodenal lipid, but not glucose, enhances gas-
tric mechanosensitivity in patients with FD but not in healthy 
subjects.
31 Moreover, in FD patients, nausea is more common 
during lipid than glucose infusion and does not occur during 
saline. Healthy controls do not experience any symptoms during 
any infusion. These findings suggest the presence of duodenal 
hypersensitivity to lipid in FD patients.
31 Thus, duodenal lipid 
can be involved in the generation of dyspeptic symptoms through 
duodenal hypersensitivity to lipid and its enhancing effects on 
gastric sensitivity. 
Long chain and medium chain triglycerides have different 
effects on perception, gastric tone, and gut hormonal release. 
Intraduodenal infusion of long chain triglycerides induces sati-
ation, fullness and nausea, reduces gastric tone, and increases 
plasma levels of cholecystokinin (CCK), gastric inhibitory poly-
peptide, neurotension, and pancreatic polypeptide. In contrast, 
intraduodenal infusion of medium chain triglycerides reduces 
gastric tone, but does not affect perception or plasma gut hor-
mone levels.
32 Therefore, long chain triglycerides seem to be 
more potent in inducing symptoms than medium chain 
triglycerides. Since gastric relaxation per se may occur without 
significant changes in plasma gut hormone levels and perception, 
symptoms associated with long chain triglycerides are likely to be 
attributed to gut hormonal changes including CCK. Indeed, dys-
peptic symptoms induced by intraduodenal lipid infusion are alle-
viated by the CCK-A receptor antagonist dexloxiglumide,
33 sug-
gesting that CCK plays a crucial role in inducing sensations asso-
ciated with intraduodenal lipid. CCK is involved in the control of 
food intake and the perception of satiety. Moreover, CCK modu-
lates upper gastrointestinal function such as gastric emptying. 
Accordingly, an altered response to CCK might lead to gastric 
motor dysfunction and dyspeptic symptoms. A CCK challenge 
test has been used to test the response to CCK. The CCK test is 
considered to be positive when the intravenous CCK-8 infusion 
reproduces the patients’ symptoms, while placebo infusion does 
not. A previous study has demonstrated that a high proportion of 
the patients with dysmotility-like FD have an abnormal response 
to CCK-8 infusion.
34 This abnormal response to CCK may play a 
role in the genesis of dyspeptic symptoms in FD. 
Therefore, duodenal lipids seem to be responsible for the 
generation of dyspeptic symptoms in FD through the induction 
of gastric motor and sensory dysfunction or the altered response 
to released CCK. Table 1 shows the summary of previous studies Kwang Jae Lee and Jan Tack
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on abnormal responses to duodenal acid or lipids in FD.
Ghrelin increases appetite and stimulates hunger. Previous 
studies revealed that ghrelin enhanced gastrointestinal motility 
and gastric emptying in humans.
35-38 Plasma ghrelin levels fall 
following meals,
39 which may become a satiety signal suppressing 
food intake. A recent study has shown abnormally low pre-
prandial ghrelin levels and the absence of significant postprandial 
decrease of ghrelin levels in a subset of dysmotility-like FD pa-
tients,
40 suggesting the role of ghrelin in the pathophysiology of 
FD. Ghrelin is produced mainly by enteroendocrine cells in the 
oxyntic glands of the stomach, which seems to be possibly modu-
lated by a vagovagal reflex. However, little is known about the in-
fluence of duodenal nutrients on ghrelin secretion, warranting 
further investigation. 
Duodenal Immune Activation in FD
Eosinophils and mast cells contribute to immune responses 
or immune activation. Mast cells induce eosoniphil migration 
and eosinophils activate mast cells.
41 Mast cells are closely related 
to enteric nerves in IBS patients
42 and increased mast cell num-
bers have been reported in the proximal and distal gut of diar-
rhea-predominant IBS patients.
43,44 Activated mast cells release 
tryptase, histamine and prostaglandin D2.
45 Mucosal mast cell 
mediators from IBS patients excite rat nociceptive visceral sen-
sory nerves, which suggests the involvement of mast cells in the 
mechanism underlying visceral hypersensitivity in IBS.
46 
Degranulation from mast cells and eosinophils leads to neural 
stimulation and smooth muscle contraction, which in turn results 
in gastrointestinal symptoms, such as abdominal pain and 
bloating.
47 While a significant increase in mast cells has not been 
observed in the duodenum of patients with FD, duodenal eosino-
philia in FD has been described.
12,48 Higher values of eosinophils 
are detected in the duodenum of dyspeptic patients, whereas gas-
tric eosinophil counts are not altered in FD. Early satiety is re-
ported to be associated with duodenal eosinophilia,
12 which 
should be explained by further studies. The association of mural 
eosinophilia and symptomatic gastric motor dysfunction has been 
demonstrated.
49 Duodenal eosinophilia has not been reported in 
patients with IBS, while duodenal mast cells are significantly in-
creased in IBS.
48 Thus, duodenal mast cell hyperplasia seems to 
be related to IBS and eosinophilia to FD. Eosinophils secrete 
multiple cytokines, chemokines and neuroactive chemicals.
45 In 
animal models, eosinophils have been suggested to cause gastro-
intestinal dysmotility and impaired gastric relaxation.
50,51 
Whether duodenal eosinophilia in humans can influence gastro-
intestinal sensory and motor function warrants further investi-
gation. Moreover, the role of duodenal eosinophilia in the genesis 
of dyspeptic symptoms needs to be further studied. 
Like post-infectious IBS, some patients develop FD after an 
acute gastroenteritis. In a recent study, prevalence of dyspepsia 
and IBS during a 1-year follow-up in a cohort of adult patients af-
fected by a Salmonella gastroenteritis outbreak was prospectively 
evaluated.
52 Both dyspepsia and IBS were significantly more 
prevalent in exposed subjects compared with unexposed 
subjects.
52 These findings suggest development of FD after acute 
inflammatory insult, which is called PI-FD. An increased num-
ber of lamina propria T cells, mast cells, and enterochromaffin 
cells have been observed in the colon or ileum of patients who 
have developed PI-IBS.
43,44 The mediators released by these acti-
vated cells may stimulate sensory afferent pathways and induce 
visceral hyperalgesia. Whether these inflammatory changes are 
simultaneously involved in the upper and lower gastrointestinal 
tract has not been previously studied. PI-FD is associated with 
persisting focal T-cell aggregates, decreased CD4+ cells and in-
creased macrophages in the duodenum.
13 Enterochromaffin cell 
counts are not altered in PI-FD.
13 Early satiety, weight loss, nau-
sea and vomiting are more frequently reported in patients with 
presumed PI-FD.
53 Helicobacter pylori (H. pylori) infection, gas-
tric emptying, and gastric sensitivity do not seem to be associated 
with PI-FD, whereas a high prevalence of impaired gastric ac-
commodation is observed in patients with presumed PI-FD.
54 
This impairment is suggested to be attributable to a dysfunction 
at the level of gastric nitrergic neurons. It is conceivable that H. 
pylori infection influences duodenal immune cells. Indeed, the 
number of duodenal intraepithelial lymphocytes is significantly 
increased in H. pylori positive FD patients due to a higher num-
ber of CD8+ CD3+ intraepithelial lymphocytes, although there 
is no change in H. pylori negative patients. CD95/Fas and 
HLA-DR expressing CD3+ intraepithelial lymphocytes show a 
significant reduction in the H. pylori negative FD group.
54 H. py-
lori colonization on the gastric mucosa enhances inflammatory 
cell infiltration, which may persist after the eradication of H. 
pylori.
55 Whether H. pylori infection could contribute to immune 
activation observed in the duodenal mucosa of H. pylori positive 
FD patients should be further investigated. The causative factors 
related to the development of PI-FD and the role of duodenal 
immune activation in the generation of dyspeptic symptoms need 
further investigation. Table 2 shows the summary of previous 
studies on duodenal immune activation in FD.Duodenum in FD
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Figure 1. Duodenal implications in 
the pathophysiology of functional dys-
pepsia. CCK, cholecystokinin.
Table 2. Studies on Duodenal Immune Activation in Functional Dyspepsia
Study Subjects Methods Results
Gargala et al,
54 26 FD patients Duodenal biopsy Higher numbers of CD8+ CD3+ IELs in H. pylori (+) FD 
  2007   12 controls Counts of IELs    patients and lower numbers of CD95/Fas and HLA-DR 
  in the duodenum   expressing CD3+ IELs in H. pylori (-) FD patients
Talley et al,
12 51 FD patients Duodenal and  FD patients have duodenal eosinophilia, but normal gastric
  2007   48 controls   gastric biopsy   eosinophil counts
Eosinophil counts  in the  Early satiety is associated with duodenal eosinophilia.
  duodenum and stomach
Walker et al,
48 51 FD patients Duodenal biopsy Duodenal eosinophilia but no mast cell hyperplasia in FD patients
  2009   48 controls Counts of eosinophils 
  and mast cells
Kindt et al,
13 12 unspecified-onset Duodenal biopsy Persisting focal T-cell aggregates, decreased CD4+ cells and 
  2009    FD Counts of CD4+, CD8+,    increased macrophage counts in PI-FD
12 PI-FD   CD68+ cells and EC  Comparable EC numbers
FD, functional dyspepsia; PI-FD, post-infectious functional dyspepsia; IELs, intraepithelial lymphocytes; EC, enterochromaffin cells; H. pylori, Helicobacter pylori.
Conclusion
Several recent studies have suggested the involvement of du-
odenal abnormalities in the pathophysiology of FD. Figure 1 de-
picts duodenal implications in the pathophysiology of FD. 
Duodenal abnormalities observed in FD patients include duode-
nal hypersensitivity to acid, increased duodenal acid exposure, 
abnormal responses to duodenal l i p i d s  o r  r e l e a s e d  c h o l -
ecystokinin, and duodenal immune activation. Whether these ab-
normalities in the duodenum play a crucial role in the generation 
of dyspeptic symptoms needs to be further elucidated. Further 
investigations on the relationship between duodenal abnormal-
ities and well-known pathophysiologic mechanisms of FD are 
required. Furthermore, the causative factors related to the devel-
opment of duodenal abnormalities in FD warrant further study. 
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